TherapeuticsMD adopts bylaw amendment facilitating acquisition by Athene Parent via tender offer and merger

TherapeuticsMD, Inc.

Bylaw amendment adopted May 27, 2022, makes Nevada control share statutes inapplicable to the merger agreement with Athene Parent and Merger Sub.
Amendment enables cash tender offer for all outstanding TXMD common stock and subsequent merger.
This 8-K/A corrects item number from 1.01 to 5.03; no disclosure changes from the original June 3, 2022 filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.